{
  "id": 7351071,
  "title": "Cellectis quits CAR-T and pivots to ‘in vivo’ gene editing",
  "url": "https://urgent.news/2026/09/14/cellectis-quits-car-t-and-pivots-to-in-vivo-gene-editing",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-14T15:46:00.000Z",
  "source": {
    "name": "BioPharma Dive",
    "slug": "biopharma-dive",
    "url": "https://www.biopharmadive.com/news/cellectis-restructure-in-vivo-gene-editing-allogeneic-heart-disease/830281/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Long a frontrunner in donor-derived cell therapy research, the French biotech cited a shifting landscape in changing course and choosing to offload its lead programs.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}